• 제목/요약/키워드: therapeutic target

검색결과 937건 처리시간 0.032초

Butein Disrupts Hsp90's Molecular Chaperoning Function and Exhibits Anti-proliferative Effects Against Drug-resistant Cancer Cells

  • Seo, Young Ho
    • Bulletin of the Korean Chemical Society
    • /
    • 제34권11호
    • /
    • pp.3345-3349
    • /
    • 2013
  • Hsp90 shows great promise as a therapeutic target due to its potential to disable multiple signaling pathways simultaneously. In this study, we discovered that a natural product, butein moderately inhibited the growth of drug-resistant cancer cells (A2780cis and H1975), and brought about the degradation of oncogenic Hsp90 client proteins. The study demonstrated that butein would be a therapeutic lead to circumvent drug-resistance in cancer chemotherapy. The structure-based screening, synthesis, and biological evaluation of butein are described herein.

Tumor Immune Microenvironment as a New Therapeutic Target for Hepatocellular Carcinoma Development

  • Eunjeong Kim
    • 한국발생생물학회지:발생과생식
    • /
    • 제27권4호
    • /
    • pp.167-174
    • /
    • 2023
  • Development of hepatocellular carcinoma (HCC) is driven by a multistep and long-term process. Because current therapeutic strategies are limited for HCC patients, there are increasing demands for understanding of immunotherapy, which has made technological and conceptual innovations in the treatment of cancer. Here, I discuss HCC immunotherapy in the view of interaction between liver resident cells and immune cells.

Target Prediction Based On PPI Network

  • Lee, Taekeon;Hwang, Youhyeon;Oh, Min;Yoon, Youngmi
    • 한국컴퓨터정보학회논문지
    • /
    • 제21권3호
    • /
    • pp.65-71
    • /
    • 2016
  • To reduce the expenses for development a novel drug, systems biology has been studied actively. Target prediction, a part of systems biology, contributes to finding a new purpose for FDA(Food and Drug Administration) approved drugs and development novel drugs. In this paper, we propose a classification model for predicting novel target genes based on relation between target genes and disease related genes. After collecting known target genes from TTD(Therapeutic Target Database) and disease related genes from OMIM(Online Mendelian Inheritance in Man), we analyzed the effect of target genes on disease related genes based on PPI(Protein-Protein Interactions) network. We focused on the distinguishing characteristics between known target genes and random target genes, and used the characteristics as features for building a classifier. Because our model is constructed using information about only a disease and its known targets, the model can be applied to unusual diseases without similar drugs and diseases, while existing models for finding new drug-disease associations are based on drug-drug similarity and disease-disease similarity. We validated accuracy of the model using LOOCV of ten times and the AUCs were 0.74 on Alzheimer's disease and 0.71 on Breast cancer.

암 치료 표적으로써 cathepsin S (Cathepsin S as a Cancer Therapeutic Target)

  • 우선민;권택규
    • 생명과학회지
    • /
    • 제28권6호
    • /
    • pp.753-763
    • /
    • 2018
  • Cathepsin은 리소좀에 존재하는 효소로, 엔도좀-리소좀 경로를 통하여 손상된 단백질의 분해를 유도한다. 이러한 cathepsin은 활성화되는 촉매 잔기 위치(catalytic residue site)에 따라 cysteine, aspartate, serine cathepsin으로 나뉜다. 다양한 암세포에서 cysteine cathepsin은 유전자 증폭이나 전사, 번역, 전사 후 단계를 통해 높은 발현을 유지한다. 특히 cathepsin S의 경우, 다른 cysteine cathepsin과 달리 중성 pH 환경에서도 안정적으로 활성도를 유지하며 특정 조직에서 발현이 제한적이라는 특징을 가지고 있기 때문에 질병의 미세환경에서 중요한 역할을 한다. 면역세포에서의 cathepsin S는 불변 사슬(invariant chain)을 분해하여 항원 제시에 중요한 MHC class II의 활성화를 통해 면역 반응을 조절하며, 암세포에서의 cathepsin S는 전이와 혈관신생을 조절함으로써 암세포의 성장을 증가시키는 역할을 한다. Cathepsin S의 발현 조절에 문제가 생기면 암, 관절염, 심혈관 질환을 포함한 많은 병리학적 현상에 영향을 미친다. 특히 암세포에서 cathepsin S의 발현 억제와 결함은 혈관신생을 억제시킬 뿐만아니라, 암세포의 성장과 전이를 감소시키고 세포사멸을 유도한다. 따라서, cathepsin S는 암 치료에 있어 좋은 표적이 될 수 있다.

Structural Maintenance of Chromosomes 4 is a Predictor of Survival and a Novel Therapeutic Target in Colorectal Cancer

  • Feng, Xiao-Dong;Song, Qi;Li, Chuan-Wei;Chen, Jian;Tang, Hua-Mei;Peng, Zhi-Hai;Wang, Xue-Chun
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권21호
    • /
    • pp.9459-9465
    • /
    • 2014
  • Background: Structural maintenance of chromosomes 4 (SMC-4) is a chromosomal ATPase which plays an important role in regulate chromosome assembly and segregation. However, the role of SMC-4 in the incidence of malignancies, especially colorectal cancer is still poorly understood. Materials and Methods: We here used quantitative PCR and Western blot analysis to examine SMC-4 mRNA and protein levels in primary colorectal cancer and paired normal colonic mucosa. SMC-4 clinicopathological significance was assessed by immunohistochemical staining in a tissue microarray (TMA) in which 118 cases of primary colorectal cancer were paired with noncancerous tissue. The biological function of SMC-4 knockdown was measured by CCK8 and plate colony formation assays. Fluorescence detection has been used to detect cell cycling and apoptosis. Results: SMC-4 expression was significantly higher in colorectal cancer and associated with T stage, N stage, AJCC stage and differentiation. Knockdown of SMC-4 expression significantly suppressed the proliferation of cancer cells and degraded its malignant degree. Conclusions: Our clinical and experimental data suggest that SMC-4 may contribute to the progression of colorectal carcinogenesis. Our study provides a new therapeutic target for colorectal cancer treatment.

Validation of Neurotensin Receptor 1 as a Therapeutic Target for Gastric Cancer

  • Akter, Hafeza;Yoon, Jung Hwan;Yoo, Young Sook;Kang, Min-Jung
    • Molecules and Cells
    • /
    • 제41권6호
    • /
    • pp.591-602
    • /
    • 2018
  • Gastric cancer is the fifth most common type of malignancy worldwide, and the survival rate of patients with advanced-stage gastric cancer is low, even after receiving chemotherapy. Here, we validated neurotensin receptor 1 (NTSR1) as a potential therapeutic target in gastric cancer. We compared NTSR1 expression levels in sixty different gastric cancer-tissue samples and cells, as well as in other cancer cells (lung, breast, pancreatic, and colon), by assessing NTSR1 expression via semi-quantitative real-time reverse transcription polymerase chain reaction, immunocytochemistry and western blot. Following neurotensin (NT) treatment, we analyzed the expression and activity of matrix metalloproteinase-9 (MMP-9) and further determined the effects on cell migration and invasion via wound-healing and transwell assays. Our results revealed that NTSR1 mRNA levels were higher in gastric cancer tissues than non-cancerous tissues. Both of NTSR1 mRNA levels and expression were higher in gastric cancer cell lines relative to levels observed in other cancer-cell lines. Moreover, NT treatment induced MMP-9 expression and activity in all cancer cell lines, which was significantly decreased following treatment with the NTSR1 antagonist SR48692 or small-interfering RNA targeting NTSR1. Furthermore, NT-mediated metastases was confirmed by observing epithelial-mesenchymal transition markers SNAIL and E-cadherin in gastric cancer cells. NT-mediated invasion and migration of gastric cancer cells were reduced by NTSR1 depletion through the Erk signaling. These findings strongly suggested that NTR1 constitutes a potential therapeutic target for the inhibition of gastric cancer invasion and metastasis.

Targeting cell surface glucose-regulated protein 94 in gastric cancer with an anti-GRP94 human monoclonal antibody

  • Hyun Jung Kim;Yea Bin Cho;Kyun Heo;Ji Woong Kim;Ha Gyeong Shin;Eun-bi Lee;Seong-Min Park;Jong Bae Park;Sukmook Lee
    • BMB Reports
    • /
    • 제57권4호
    • /
    • pp.188-193
    • /
    • 2024
  • Gastric cancer (GC), a leading cause of cancer-related mortality, remains a significant challenge despite recent therapeutic advancements. In this study, we explore the potential of targeting cell surface glucose-regulated protein 94 (GRP94) with antibodies as a novel therapeutic approach for GC. Our comprehensive analysis of GRP94 expression across various cancer types, with a specific focus on GC, revealed a substantial overexpression of GRP94, highlighting its potential as a promising target. Through in vitro and in vivo efficacy assessments, as well as toxicological analyses, we found that K101.1, a fully human monoclonal antibody designed to specifically target cell surface GRP94, effectively inhibits GC growth and angiogenesis without causing in vivo toxicity. Furthermore, our findings indicate that K101.1 promotes the internalization and concurrent downregulation of cell surface GRP94 on GC cells. In conclusion, our study suggests that cell surface GRP94 may be a potential therapeutic target in GC, and that antibody-based targeting of cell surface GRP94 may be an effective strategy for inhibiting GRP94-mediated GC growth and angiogenesis.

다양한 Plugging 형태를 이용한 감마나이프의 선택적 빔 차폐 방법 (Selective Beam Shielding Method of Gamma-Knife Unit Using Various Plugging Patterns)

  • 장건호;임영진;신동오;최두호;홍성언;임언
    • Radiation Oncology Journal
    • /
    • 제11권2호
    • /
    • pp.439-448
    • /
    • 1993
  • Leksell 감마나이프(B-형)가 1992년 3월 경희대학교 의과대학 병원에 설치되었다. 선택적 빔 Plugging방법을 이용하여 정상 민감 조직에 대한 저선량 분포를 현저히 줄일 수 있으며, 또한 치료 부위에 더 좋은 선량 분포를 얻을 수 있다. 저선량에 대한 여러가지 선량 분포의 변화에 대한 연구를 하였으며, 사용중인 KULA프로그램의 선량 분포 곡선을 평가하기 위해 필름을 이용한 방사선량 계측을 실시하였고, RFA-3자동 밀도 측정기를 이용하여 평가하였다. 1992년 3월부터 1993년 2월까지 1년동안 100명의 환자중 17명의 환자에 선택적 빔 차폐 방법이 적용되었다. 고선량 영역에서는 측정값과 프로그램에서 제공된 선량 분포가 잘 일치하였다. 뇌하수체 선종의 치료시 치료 부위가 클 경우에는 본 연구 방법의 적용이 매우 중요시 되었으며, 반면에 치료 영역이 작을 경우에는 적절한 헬맷의 선택이 중요함을 알 수 있었다. 치료 환자의 중요 민감 장기의 방사선 선량 평가에서는 뇌간에 3~12 Gy, 시신경 교차에 3~11.2 Gy이었다. 중추신경계 영역의 최적화된 치료를 위하여 다양한 Plugging형태를 임상에 적용하는 것이 방사선에 민감한 정상 조직을 보호하기 위해 매우 중요한 인자가 됨을 알았다.

  • PDF

TOMM20 as a potential therapeutic target of colorectal cancer

  • Park, Sang-Hee;Lee, Ah-Reum;Choi, Keonwoo;Joung, Soyoung;Yoon, Jong-Bok;Kim, Sungjoo
    • BMB Reports
    • /
    • 제52권12호
    • /
    • pp.712-717
    • /
    • 2019
  • Translocase of outer mitochondrial membrane 20 (TOMM20) plays an essential role as a receptor for proteins targeted to mitochondria. TOMM20 was shown to be overexpressed in various cancers. However, the oncological function and therapeutic potential for TOMM20 in cancer remains largely unexplored. The purpose of this study was to elucidate the underlying molecular mechanism of TOMM20's contribution to tumorigenesis and to explore the possibility of its therapeutic potential using colorectal cancer as a model. The results show that TOMM20 overexpression resulted in an increase in cell proliferation, migration, and invasion of colorectal cancer (CRC) cells, while siRNA-mediated inhibition of TOMM20 resulted in significant decreases in cell proliferation, migration, and invasion. TOMM20 expression directly impacted the mitochondrial function including ATP production and maintenance of membrane potential, which contributed to tumorigenic cellular activities including regulation of S phase cell cycle and apoptosis. TOMM20 was overexpressed in CRC compared to the normal tissues and increased expression of TOMM20 to be associated with malignant characteristics including a higher number of lymph nodes and perineural invasion in CRC. Notably, knockdown of TOMM20 in the xenograft mouse model resulted in a significant reduction of tumor growth. This is the first report demonstrating a relationship between TOMM20 and tumorigenesis in colorectal cancer and providing promising evidence for the potential for TOMM20 to serve as a new therapeutic target of colorectal cancer.

Tumor Stroma as a Therapeutic Target for Pancreatic Ductal Adenocarcinoma

  • Dae Ui Lee;Beom Seok Han;Kyung Hee Jung;Soon-Sun Hong
    • Biomolecules & Therapeutics
    • /
    • 제32권3호
    • /
    • pp.281-290
    • /
    • 2024
  • Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis owing to its desmoplastic stroma. Therefore, therapeutic strategies targeting this tumor stroma should be developed. In this study, we describe the heterogeneity of cancer-associated fibroblasts (CAFs) and their diverse roles in the progression, immune evasion, and resistance to treatment of PDAC. We subclassified the spatial distribution and functional activity of CAFs to highlight their effects on prognosis and drug delivery. Extracellular matrix components such as collagen and hyaluronan are described for their roles in tumor behavior and treatment outcomes, implying their potential as therapeutic targets. We also discussed the roles of extracellular matrix (ECM) including matrix metalloproteinases and tissue inhibitors in PDAC progression. Finally, we explored the role of the adaptive and innate immune systems in shaping the PDAC microenvironment and potential therapeutic strategies, with a focus on immune cell subsets, cytokines, and immunosuppressive mechanisms. These insights provide a comprehensive understanding of PDAC and pave the way for the development of prognostic markers and therapeutic interventions.